A. Cheng

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.

Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study

V. Breder, B. Ryoo, Z. Ramji, 2024, Cancer.